The National Plan for Epilepsy Act adds a new Section 320C to the Public Health Service Act, directing the Secretary of Health and Human Services to implement a coordinated federal strategy to prevent, diagnose, treat, and ultimately cure epilepsy. The statute requires development and periodic updates of an integrated national plan, coordination across Federal agencies, information about the Federal investment level in epilepsy, and measures to improve diagnosis, care coordination, and quality of life for people with epilepsy and their caregivers.
The bill also establishes an Advisory Council to advise HHS, sets out recurring assessments and reports to Congress, mandates data-sharing from agencies with epilepsy-related information, and includes a sunset date in 2035. For professionals in health agencies, research institutions, and patient advocacy groups, the Act creates a formal federal architecture for prioritizing epilepsy research, surveillance, and care — but it does not itself appropriate funding for these activities within the text of the bill.
At a Glance
What It Does
The bill tasks the HHS Secretary with running a ‘‘National Plan for Epilepsy’’ that integrates federal research and service activities, solicits public input, and produces recurring evaluations of progress. It requires coordination across agencies, encourages development of treatments and care improvements, and obliges agencies holding epilepsy data to share it with HHS.
Who It Affects
Federal agencies with epilepsy-related programs (NIH, CDC, FDA, CMS, HRSA, DoD, VA) will be pulled into cross-agency coordination; researchers, clinical specialists (including epileptologists), nonprofits, and people living with epilepsy will engage through the Advisory Council and public comment processes. State and local public-health surveillance and clinical networks may be tapped for data and implementation support.
Why It Matters
This creates a permanent federal vehicle to prioritize epilepsy across research, clinical care, and public health and formalizes reporting lines to Congress. For stakeholders, the Act can concentrate attention on surveillance gaps, treatment development, and disparities — provided agencies and Congress supply resources to act on the plan’s recommendations.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill inserts a new program into the Public Health Service Act called the ‘‘National Plan for Epilepsy.’’ HHS must develop, maintain, and periodically update a single, integrated strategy that spans prevention, diagnosis, treatment, care coordination, and efforts toward a cure. The statute lists specific activities the plan must address, from estimating Federal investment levels to encouraging development of new therapies and improving early diagnosis and care coordination.
A separate annual assessment obligation starts within two years of enactment: the Secretary must evaluate the Nation’s readiness and response to epilepsy and recommend priority actions. Parallel to that, the law creates an Advisory Council on Epilepsy Research, Care, and Services composed of both Federal representatives and a set number of expert non‑Federal members drawn from people with epilepsy, caregivers, clinicians, researchers, and nonprofits.
The Council must meet at least quarterly, hold meetings open to the public, and convene a broader federal/non‑federal research meeting on a biennial basis.Reporting is multi‑layered. The Advisory Council must deliver an initial report to the Secretary and Congress within 18 months and then every two years, evaluating federally funded efforts and making prioritized recommendations (covering surveillance, access to specialized care, reducing disparities, preventing epilepsy deaths, and financial impacts on families, among other items).
Separately, the Secretary must submit an annual report to Congress describing federally funded epilepsy activities, priority actions, implementation steps, and progress made in carrying out the National Plan. To support those reports, the statute requires agencies inside and outside HHS that hold epilepsy-related data to share it with the Secretary.
Finally, the new authority is temporary: the section will expire on December 31, 2035.
The Five Things You Need to Know
The statute is added to law as Section 320C of Part B, Title III of the Public Health Service Act (42 U.S.C. 243 et seq.).
The Secretary must produce an estimate of the level of Federal investment in preventing, diagnosing, treating, and curing epilepsy as part of the information the National Plan provides.
The Advisory Council’s non‑Federal membership is tightly prescriptive: 4 people living with different types of epilepsy, 2 family caregivers, 2 licensed or accredited providers (including at least one epileptologist or neurologist), 2 biomedical researchers, and 3 representatives from separate epilepsy nonprofits.
All Advisory Council meetings must be open to the public and the Council must meet at least quarterly; it must also convene a joint Federal/non‑Federal epilepsy research meeting not later than two years after enactment and then every two years.
The new Section 320C includes an explicit sunset clause — it expires on December 31, 2035.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Creation of the National Plan for Epilepsy
This provision directs the HHS Secretary to run a national project called the National Plan for Epilepsy focused on prevention, diagnosis, treatment, and cure. It enumerates core activities (labelled A–J in the bill) that range from drafting an integrated plan and estimating Federal investment to coordinating research across agencies and encouraging therapy development. Practically, this places responsibility for cross‑cutting strategic leadership at HHS but does not itself appropriate money; implementation will depend on agency budgets and interagency cooperation.
Annual assessment requirement
Subsection (b) requires HHS to complete an assessment of the Nation’s progress on epilepsy not later than two years after enactment and then annually. The assessment must recommend priority actions and outline steps taken or needed to implement them. For operational teams, this creates a recurring analytical deliverable that should inform budget requests, program design, and performance tracking.
Advisory Council on Epilepsy Research, Care, and Services
The bill establishes an advisory body composed of specified Federal agency representatives (NIH, CMS, CDC, FDA, HRSA, DoD, VA) and a defined slate of non‑Federal experts representing patients, caregivers, clinicians, researchers, and nonprofits. The Council must meet at least quarterly, hold public meetings, and provide a substantive report to the Secretary and Congress 18 months after enactment and biennially thereafter. That report must evaluate federally funded epilepsy efforts and make prioritized recommendations — a mechanism intended to inject stakeholder perspectives into HHS planning.
Annual reporting to Congress and data‑sharing mandate
Subsection (d) directs the Secretary to send an annual report to Congress that evaluates federally funded epilepsy activities, contains priority actions and implementation steps, and documents progress on the National Plan. Subsection (e) obligates agencies inside and outside HHS that possess epilepsy data to share it with the Secretary to enable those reports. Operationally, this creates interagency data dependencies and will surface practical issues around data access, privacy, and interoperability between federal systems.
Sunset
The final subsection provides that the new statutory section expires on December 31, 2035. The finite duration means the National Plan and the Council are established for roughly a decade, which shapes expectations for long‑range program development, evaluations, and any required reauthorization or extension discussions.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People living with epilepsy and their caregivers — the law prioritizes early diagnosis, coordinated care, surveillance improvements, and measures to reduce stigma, financial burden, and epilepsy‑related mortality.
- Epilepsy researchers and clinical investigators — the coordinated plan and Advisory Council create a visible federal structure to align research priorities, highlight gaps, and encourage translational and therapeutic development.
- Specialized clinical programs and epileptologists — the Act emphasizes expanding access to expert and specialized care, which can support network development, referrals, and reimbursement advocacy.
- Patient advocacy organizations — the statute requires nonprofit representation on the Advisory Council and public comment solicitation, giving advocacy groups formal influence on recommendations and priority setting.
- Veterans and service members — inclusion of DoD and VA on the Council signals attention to epilepsy as it affects military populations and could improve coordination of care for those beneficiaries.
Who Bears the Cost
- HHS (the Secretary’s office) — administrative and program management responsibility to run the National Plan, produce assessments and annual reports, convene the Advisory Council, and coordinate data collection without dedicated funding in the bill text.
- Federal partner agencies (NIH, CDC, FDA, CMS, HRSA, DoD, VA) — must allocate staff time and data resources to coordination, reporting, and information sharing; agencies may need to reassign existing resources or seek appropriations.
- Researchers and clinical sites — when called on for data, participation in Council meetings, or to implement recommended surveillance and care standards, they may face additional reporting burdens and operational changes.
- Nonprofit organizations and patient representatives — the Act expects sustained engagement in Council work and public consultations, which requires staffing and resource commitments that smaller groups may find taxing.
Key Issues
The Core Tension
The central dilemma is between concentrated federal coordination — which can reduce fragmentation in epilepsy research, surveillance, and care — and the reality that the bill imposes coordination and reporting obligations without specifying new funding; that combination risks producing detailed plans and recommendations that agencies cannot fully implement, shifting the burden onto already stretched programs and outside stakeholders.
The statute creates structure and obligation without authorizing dedicated new appropriations within the text. That means HHS and partner agencies must implement the National Plan using existing budgets or await separate appropriations, a practical constraint that may limit the plan’s effectiveness.
The requirement that agencies both inside and outside HHS share epilepsy data with the Secretary is purposive but raises immediate questions about legal authority, data standards, privacy protections (HIPAA and other statutes), and IT interoperability across disparate federal systems.
Another implementation tension concerns the Advisory Council design. The bill prescribes specific member categories to ensure lived‑experience and scientific expertise are represented, which strengthens legitimacy; at the same time, the narrow membership and public meeting requirements could make the Council slower to act and susceptible to competing stakeholder agendas.
Finally, the statutory sunset in 2035 creates a defined window for impact but may discourage long‑term infrastructure investments unless Congress later extends or replaces the authority.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.